Form 4 Ascendis Pharma A/S For: 29 September
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ascendis Pharma AS ADR (ASND)
Ascendis Pharma AS ADR stock price live, this page displays NASDAQ ASND stock exchange data. View the ASND premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ascendis Pharma AS ADR real time stock price chart below.
What Is the Ascendis Pharma AS ADR Stock Price Today?
The Ascendis Pharma AS ADR stock price today is 229.23.
What Is the Stock Symbol for Ascendis Pharma AS ADR?
The stock symbol for Ascendis Pharma AS ADR is "ASND."
What Stock Exchange Does Ascendis Pharma AS ADR Trade On?
Ascendis Pharma AS ADR is listed and trades on the NASDAQ stock exchange.
Is Ascendis Pharma AS ADR a Good Stock to Buy?
Determining whether Ascendis Pharma AS ADR, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ASND quote. (ISIN: DK0060615755)
What Is the Ascendis Pharma AS ADR Stock Price Today?
The Ascendis Pharma AS ADR stock price today is 229.23.
What Is the Stock Symbol for Ascendis Pharma AS ADR?
The stock symbol for Ascendis Pharma AS ADR is "ASND."
What Stock Exchange Does Ascendis Pharma AS ADR Trade On?
Ascendis Pharma AS ADR is listed and trades on the NASDAQ stock exchange.
Is Ascendis Pharma AS ADR a Good Stock to Buy?
Determining whether Ascendis Pharma AS ADR, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ASND quote. (ISIN: DK0060615755)
Fair Value
An estimate of a Ascendis Pharma AS ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
223.96
233.96
52 wk Range
186.05
282.15
ASND is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Ascendis Pharma AS ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
223.96233.96
52 wk Range
186.05282.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ASND Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Ascendis Pharma AS ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
307.25
Upside
+34.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
20 Buy
0 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 307.25
(+34.03% Upside)
Ascendis Pharma AS ADR SWOT Analysis
Pipeline Promise | Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development. |
Market Dominance | Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients. |
Financial Trajectory | Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026. |
Analyst Optimism | Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25. |
Ascendis Pharma AS ADR Earnings Call Summary for Q2/2026
- Ascendis beat Q2 2026 estimates with EPS of $2.83 vs. $1.51 expected and revenue of $339.3M vs. $326.5M, driven by rare-disease portfolio growth.
- YORVIPATH led with EUR 252M in revenue; SKYTROFA added EUR 55M; new launch UBEGLA contributed EUR 8M in its first quarter on market.
- Management reaffirmed EUR 500M+ operating cash flow target for 2026 and long-term goal of EUR 5B revenue by 2030 despite heavy R&D spending.
- YUVIWEL regulatory decisions expected Q4 2026 in U.S. and Europe; early uptake strong with 220+ patients enrolled and 65%+ reimbursement approval.
- Shares fell 2.4% to $249.28 despite beat as investors weighed patent litigation with BioMarin and profit boost from EUR 158M priority review voucher sale.
Last Updated: 13/08/2026, 14:44
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
2.83 / 1.51
Revenue / Forecast
339.28M / 326.45M
Compare ASND to Peers and Sector
Metrics to compare | ASND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASNDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 18.1x | −3.0x | −0.3x | |
PEG Ratio | 0.05 | −0.04 | 0.00 | |
Price/Book | 9.4x | 1.8x | 2.6x | |
Price / LTM Sales | 12.8x | 5.3x | 3.0x | |
Upside (Analyst Target) | 34.0% | 111.9% | 61.2% | |
Fair Value Upside | Unlock | −5.2% | 7.2% | Unlock |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Ascendis Pharma AS ADR (ASND) Stock Price Today?
The Ascendis Pharma AS ADR stock price today is 229.23 USD.
What Stock Exchange Does Ascendis Pharma AS ADR Trade On?
Ascendis Pharma AS ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Ascendis Pharma AS ADR?
The stock symbol for Ascendis Pharma AS ADR is "ASND."
What Is the Ascendis Pharma AS ADR Market Cap?
As of today, Ascendis Pharma AS ADR market cap is 15.05B USD.
What Is Ascendis Pharma AS ADR's Earnings Per Share (TTM)?
The Ascendis Pharma AS ADR EPS (TTM) is 11.72.
When Is the Next Ascendis Pharma AS ADR Earnings Date?
Ascendis Pharma AS ADR will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is ASND a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Ascendis Pharma AS ADR Stock Split?
Ascendis Pharma AS ADR has split 0 times.
How Many Employees Does Ascendis Pharma AS ADR Have?
Ascendis Pharma AS ADR has 1189 employees.
What is the current trading status of Ascendis Pharma AS ADR (ASND)?
As of Oct 11, 2026, Ascendis Pharma AS ADR (ASND) is trading at a price of 229.23 USD, with a previous close of 229.23 USD. The stock has fluctuated within a day range of 223.96 USD to 233.96 USD, while its 52-week range spans from 186.05 USD to 282.15 USD.
What Is Ascendis Pharma AS ADR (ASND) Price Target According to Analysts?
The average 12-month price target for Ascendis Pharma AS ADR is 307.25 USD, with a high estimate of 349.55528173 USD and a low estimate of 261.98498936 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +34.03% Upside potential.
What Is the ASND Premarket Price?
ASND's last pre-market stock price is 225.00 USD. The pre-market share volume is 210.00, and the stock has decreased by 2.31, or 1.04%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.